CA2667177C - Slpa as a tool for recombinant protein and enzyme technology - Google Patents

Slpa as a tool for recombinant protein and enzyme technology Download PDF

Info

Publication number
CA2667177C
CA2667177C CA2667177A CA2667177A CA2667177C CA 2667177 C CA2667177 C CA 2667177C CA 2667177 A CA2667177 A CA 2667177A CA 2667177 A CA2667177 A CA 2667177A CA 2667177 C CA2667177 C CA 2667177C
Authority
CA
Canada
Prior art keywords
fusion protein
s1pa
protein
polypeptide
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2667177A
Other languages
English (en)
French (fr)
Other versions
CA2667177A1 (en
Inventor
Elke Faatz
Peter Schaarschmidt
Urban Schmitt
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2667177A1 publication Critical patent/CA2667177A1/en
Application granted granted Critical
Publication of CA2667177C publication Critical patent/CA2667177C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
CA2667177A 2008-05-26 2009-05-25 Slpa as a tool for recombinant protein and enzyme technology Active CA2667177C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08009537A EP2127678A1 (en) 2008-05-26 2008-05-26 SlpA as a tool for recombinant protein and enzyme technology
EP08009537.5 2008-05-26

Publications (2)

Publication Number Publication Date
CA2667177A1 CA2667177A1 (en) 2009-11-26
CA2667177C true CA2667177C (en) 2017-08-15

Family

ID=39590486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2667177A Active CA2667177C (en) 2008-05-26 2009-05-25 Slpa as a tool for recombinant protein and enzyme technology

Country Status (6)

Country Link
US (2) US8263086B2 (enExample)
EP (2) EP2127678A1 (enExample)
JP (1) JP5611540B2 (enExample)
CN (1) CN101591665B (enExample)
CA (1) CA2667177C (enExample)
ES (1) ES2590340T3 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617731A1 (en) * 2012-01-19 2013-07-24 Roche Diagnostics GmbH Soluble immunoreactive Treponema pallidum TpN47 antigens
EP2706115A1 (en) * 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
EP2827146A1 (en) * 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
CN105829892B (zh) * 2013-12-19 2018-06-12 英特维特国际股份有限公司 Csfv抗体的改进的诊断测试
EP2913338A1 (en) * 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
US10562943B2 (en) 2014-10-24 2020-02-18 University Of Florida Research Foundation, Incorporated Lactobacillus acidophilus surface layer protein A (SlpA) as a therapeutic agent for the treatment of inflammatory diseases
CA2966358C (en) 2014-12-01 2021-12-07 Pfenex Inc. Fusion partners for peptide production
EP3465216B1 (en) 2016-05-31 2020-04-08 Roche Diagnostics GmbH Pretreatment method for rapid detection of hcv core antigen
BR112018072042A2 (pt) 2016-05-31 2019-03-12 Hoffmann La Roche métodos de detecção de polipeptídeo e de processamento prévio de amostras, reagente de processamento prévio, kit de detecção de hcv e uso de composição
EP3577460B1 (en) 2017-02-02 2021-01-20 Roche Diagnostics GmbH Immunoassay using at least two pegylated analyte-specific binding agents
JP7389740B2 (ja) * 2017-07-27 2023-11-30 エフ． ホフマン－ラ ロシュ アーゲー Ｈｃｖ抗原のマルチエピトープ融合タンパク質およびその使用
WO2020104397A1 (en) * 2018-11-19 2020-05-28 Bioaster Methods and reagents for multiplex binding experiments
WO2023060116A2 (en) * 2021-10-05 2023-04-13 Viro Research, Llc Herpes simplex virus types 1 and 2 lateral flow assay
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
PL218245B1 (pl) * 2001-06-22 2014-10-31 Hoffmann La Roche Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową i izomerazę peptydyloprolilową oraz kompozycja reagentów obejmująca ten kompleks
CA2636075C (en) * 2006-01-03 2011-11-08 F. Hoffmann-La Roche Ag Chimaeric fusion protein with superior chaperone and folding activities

Also Published As

Publication number Publication date
CA2667177A1 (en) 2009-11-26
EP2127678A1 (en) 2009-12-02
CN101591665A (zh) 2009-12-02
CN101591665B (zh) 2016-08-31
US20090291892A1 (en) 2009-11-26
JP2009284902A (ja) 2009-12-10
JP5611540B2 (ja) 2014-10-22
HK1138620A1 (zh) 2010-08-27
EP2127679B1 (en) 2016-06-29
US8790659B2 (en) 2014-07-29
ES2590340T3 (es) 2016-11-21
US20120308994A1 (en) 2012-12-06
EP2127679A1 (en) 2009-12-02
US8263086B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
CA2667177C (en) Slpa as a tool for recombinant protein and enzyme technology
US8247206B2 (en) Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein
AU2013211242B2 (en) Soluble immunoreactive Treponema pallidum TpN47 antigens
US8551696B2 (en) Rubella E1 envelope protein variants and their use in detection of anti-rubella antibodies
US10197559B2 (en) Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
HK1138620B (en) Slpa as a tool for recombinant protein and enzyme technology
US20250147024A1 (en) Transglutaminase substrates for labeling
HK1209784B (en) Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
HK1148026B (en) Novel rubella e1 envelope protein variants and their use in the detection of antirubella antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140523